Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
olanzapine + ondansetron
- Development stage
- Phase 3
- Lead developer
- Teva Pharmaceutical Industries
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of olanzapine (a thienobenzodiazepine derivative and atypical antipsychotic) and ondansetron (a 5-HT3 receptor antagonist) used primarily for the prevention of chemotherapy-induced nausea and vomiting (CINV). This combination is particularly effective for patients receiving highly emetogenic chemotherapy regimens, with olanzapine providing additional benefits in decreasing anxiety and depression.
02
Targets
HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)HTR3A (5-hydroxytryptamine receptor 3A)DRD2 (Dopamine D2 Receptor)
Beyond the preview
Go deeper on olanzapine + ondansetron.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on olanzapine + ondansetron.